Successfully Held in Shanghai

On August 25, 2025, the Singapore Renal Dialysis Equipment Supply & Demand Ecological Matchmaking Symposium was successfully held in Shanghai. The event was hosted by Stellar Biotech Co., Ltd. and co-organized by the Medical Device Supply Chain Branch of China Federation of Logistics & Purchasing (CFLP).

Under the theme “Deepening the Singapore Market, Building a Global Expansion Ecosystem for Domestic Renal Dialysis Devices”, the forum provided in-depth analysis of market opportunities and regulatory advantages of Singapore as an international medical hub. It focused on optimizing the supply-demand ecosystem, offering targeted insights and practical solutions for domestic renal dialysis devices to break through bottlenecks in global expansion and enter international markets.

As an enterprise specializing in medical supply chain services, Stellar Biotech Co., Ltd. highlighted its global expansion support model of “High-quality Products + Production Capacity Guarantee + Localized Services” at the forum. Addressing Singapore’s demand for advanced dialysis technologies, the company proposed an integrated solution covering regulatory consulting, supply chain establishment, and localized operation and maintenance, helping enterprises reduce compliance costs and market access barriers.

More than 60 enterprise leaders from R&D, manufacturing, and distribution of renal dialysis equipment attended the meeting. Discussions focused on Singapore medical regulatory compliance, clinical demand matching, and regional supply chain collaboration. Participants agreed that the precise matchmaking platform established at the forum responded to the urgent need for Chinese medical devices to “go global with technology” and met Singapore’s demand for reliable dialysis equipment, laying a foundation for deeper integration of the Chinese and international medical ecosystems.

General Manager of Stellar Biotech Co., Ltd. General Manager Liu Weimin, on behalf of the organizer, thanked the Medical Device Supply Chain Branch of CFLP for its support and warmly welcomed all delegates. He noted that the global pharmaceutical and medical device industry is embracing new development opportunities driven by two-way demand and supply. Demand for high-quality medical products continues to grow in Singapore, Southeast Asia, Hong Kong, and Macao.

Stellar Biotech unlocks cross-border cooperation value through a full-chain model of “High-quality Products + Production Capacity Advantages + Precise Matching”, providing integrated support including regulatory registration, supply chain development, and localized services.

Secretary-General Jia Guibin of the Medical Device Supply Chain Branch of CFLP welcomed all guests and thanked Stellar Biotech Co., Ltd. for its strong support. He emphasized that the global healthcare industry is undergoing profound transformation. With rising demand and rapid technological innovation in renal dialysis, the international competitiveness of domestic dialysis devices is gradually improving, making global expansion an inevitable choice and major opportunity.

With its advanced medical system, sound regulatory framework, and superior geographical location, Singapore has become a key destination for Chinese dialysis device enterprises going global. The forum aimed to build a communication bridge, integrate resources, analyze market opportunities in Singapore, and help enterprises define their direction to create a new win-win industrial ecosystem.

Medical Director of the National Kidney Foundation (NKF), Singapore, Associate Professor Zhu Changyun expressed gratitude to the Medical Device Supply Chain Branch of CFLP and Stellar Biotech Co., Ltd., and warmly welcomed all participants. He stated that kidney diseases pose a growing health challenge in Singapore. As a critical treatment for patients with end-stage renal disease, dialysis directly affects patients' quality of life.

He looked forward to more outstanding Chinese dialysis enterprises with advanced technologies, mature products, and rich service experience entering Singapore to benefit local patients.

Assistant Director of Operations & Research Department, Medical Device Supply Chain Branch of CFLP, Chu Jiabao noted that the domestic dialysis device market boasts huge growth potential but also fierce competition, making overseas expansion a necessary strategy to ease growth bottlenecks. As a strategic hub in Southeast Asia, Singapore is one of the top choices for domestic dialysis devices going global.

It can also support multinational enterprises in R&D, registration, and manufacturing, empowering them to enter ASEAN, expand to Europe and the United States, and implement global market strategies.

Chairman and President of Shenzhen Huayuan Regenerative Medicine Co., Ltd. Zheng Lixin shared his views on the layout of the kidney diagnosis industry. Emerging technologies and new business models are reshaping the industrial chain, including cell therapy, drug-device combination products, bio-kidneys, big data, AI, and cloud platforms.

He added that the development of AI algorithms and biosensors will accelerate the miniaturization of artificial kidneys, while implantable artificial kidneys must meet clinical requirements such as biocompatibility and functional reliability.

Vice Chairman and Secretary-General of the Nephrology and Dialysis Committee, China Non-Public Medical Institutions Association. Wang Jiusheng shared industry data on hemodialysis in non-public medical institutions, presenting a comprehensive overview of the sector’s current development, diagnosis and treatment capabilities, and management effectiveness, highlighting its strong service capacity.

He also pointed out challenges such as declining fees and cost pressures in dialysis centers, and proposed suggestions including establishing a reasonable pricing mechanism and forming consensus on “four monitoring indicators”.

All guests then participated in an in-depth discussion on core topics including business development and global expansion strategies for dialysis enterprises, challenges and solutions in localized overseas operations, cooperation opportunities in renal dialysis equipment, product features, and core advantages.

During the session, guests agreed that building localized teams, strengthening cooperation with local medical institutions and enterprises, and deeply understanding local market rules are key to overcoming challenges. Meanwhile, brand building through high-quality products and services is essential to establish a strong corporate image. Cooperation across R&D, manufacturing, and market expansion can reduce costs, improve efficiency, and jointly promote the development of the renal dialysis equipment industry.

The organizer arranged an in-depth supply-demand business matchmaking session. The session featured a vibrant atmosphere with a combination of one-on-one and multi-party discussions.

Supplying enterprises presented technical parameters, performance advantages, and clinical application cases of dialysis machines, dialyzers, tubing sets, and other devices, elaborating on their core competitiveness. Buyers raised specific requirements based on their Singapore market experience, including product specifications compliant with local medical standards, delivery cycles, and after-sales service.

Both sides conducted in-depth negotiations on pricing, cooperation models, and other key issues, with several enterprises reaching substantive cooperation intentions.

The conference was moderated by Wang Jing, Deputy Director of Industry Development & Service Department of the Medical Device Supply Chain Branch of CFLP.

With this, the Singapore Renal Dialysis Equipment Supply & Demand Ecological Matchmaking Symposium concluded successfully.